Biological Markers and Response to Neoadjuvant Taxane-Based Chemotherapy in Patients with Locally Advanced Breast Cancer

Table 4

Five-year OAS and DFS rates in 95 breast cancer patients according to biological prognostic factors.

Variable	5-year DFS rate (%)	5-year OAS rate (%)
Hormonal receptor (HmR) status
HmR+; (n = 74)	82.3	84
HmR−; (n = 21)	26.5	35.7
P value	P <  0.0001; HR 21.48 95%; CI 6.34–72.72	P =  0.0001; HR 11.59, 95%; CI 3.32–40.47
Her2/neo status
Her2/neo+; (n = 20)	33.8	41.7
Her2/neo−; (n = 75)	81.8	83.2
P value	P <  0.0001; HR 12.27, 95% CI 3.92–38.42	P =  0.001; HR 7.14, 95%; CI 2.21–23.06
p53 status
Inactive p53; (n = 29)	46.1	57.1
Intact p53; (n = 66)	83.6	86.7
P value	P =  0.0007; HR 5.15, 95%; CI 1.99–13.33	P =  0.0029; HR 4.81, 95%; CI 1.71–13.52